POLYTRIM
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPS
Approved
Oct 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLYTRIM is an ophthalmic antibiotic solution approved in 1988 for treating nasolacrimal duct obstruction, a condition affecting tear drainage in the eye. The product is a small-molecule formulation delivered as eye drops. Mechanism of action details are not publicly disclosed in available data.
$0.938MPart D
LOE ApproachingMinimal commercial scale with very low Part D claims (14 in 2023) suggests a niche product with limited team resources and declining commercial priorities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
POLYTRIM represents a mature, niche ophthalmic product with minimal linked job openings and declining commercial activity, typical of products approaching loss of exclusivity. Career growth on this asset is limited; professionals should expect maintenance roles rather than expansion opportunities.
Brand ManagerField Sales Representative
Worked on POLYTRIM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.